Company Profile

Bacchus Therapeutics Inc
Profile last edited on: 7/28/2022      CAGE: 8HX06      UEI: EWCHMK9ZL174

Business Identifier: Exploiting cancer's cells addiction to making lipids: enabling regression of incurable cancers
Year Founded
2019
First Award
2021
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9385 Discovery Boulevard
Manassas, VA 20109
   N/A
   N/A
   www.bacchus-therapeutics.com
Location: Single
Congr. District: 01
County: San Francisco

Public Profile

At the clinical stage of the firm's product development, Bacchus Therapeutics is a biotech company developing small molecule inhibitors of cancer metabolic pathways - novel compounds designed to exploit cancer's hypermetabolic state by targeting cancer-specific metabolic pathways. Anchored in the core concept of starving cancer cells of their need for eat and tto make fat (lipids), the firm's proprietary compounds cause regression of incurable MYC cancers and prolong survival in the firm's preclinical mouse models bearing human tumors. With a particular focus cancers caused by the MYC oncogene - responsible for 70% of human cancers - the firm's early efforts had been supported by the entrepreneurship program of SPARK at Stanford, by MBC BioLabs and AbbVie Inc. .In response to available resources. the firm - more recently - also relocated from San Francisco to the east coast and the Prince William Science Accelerator in Virginia

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Dr Felsher -- Co-Founder

  Arvin Gouw -- Founding partner and CEO

Company News

There are no news available.